Viking reports Q2 net loss of $15.4M, cash $228.3M; VK2809 VOYAGE enrollment continues

Viking Therapeutics, Inc.

2022-Q2 EPS reported -$0.38

Q2 net loss $15.4M ($0.20/sh) vs $9.6M ($0.13/sh) in Q2 2020; R&D expenses rose to $12.8M from $7.8M.
Cash, equivalents and short-term investments $228.3M at June 30, down from $248.4M at Dec 31, 2020.
Phase 2b VOYAGE study of VK2809 for NASH enrolling; top-line data expected in 2022.
VK0214 Phase 1 met primary and secondary objectives; Phase 1b proof-of-concept trial in X-ALD patients underway.
Six-month net loss $29.4M ($0.38/sh) vs $19.3M ($0.27/sh) in H1 2020.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.